Literature DB >> 29864763

Smoking in Schizophrenia: an Updated Review.

Marina Šagud1, Bjanka Vuksan-Ćusa, Nenad Jakšić, Alma Mihaljević-Peleš, Martina Rojnić Kuzman, Nela Pivac.   

Abstract

Patients with schizophrenia continue to have the highest rate of both smoking and heavy nicotine dependence. The interaction between smoking and schizophrenia is complex. There is evidence of the shared genetic background. Recent preclinical and clinical research has further investigated self-medication hypothesis, given that nicotine might alleviate cortical dysfunction. While prior research indicated some favorable effects of smoking on cognitive performance, particulatly on attention/vigilance, recent studies did not confirm those findings. Lower severity of negative symptoms in smokers was not confirmed across studies. Cigarette smoking decreases clozapine and olanzapine concentrations. There is no consistent evidence of favorable effects of nicotine on symptoms in schizophrenia, but the evidence of detrimental effects of smoking on general health is highly consistent. Smoking cessation should be a priority in patients with schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29864763

Source DB:  PubMed          Journal:  Psychiatr Danub        ISSN: 0353-5053            Impact factor:   1.063


  8 in total

1.  One-day tropisetron treatment improves cognitive deficits and P50 inhibition deficits in schizophrenia.

Authors:  Luyao Xia; Lei Liu; Xiaohong Hong; Dongmei Wang; Gaoxia Wei; Jiesi Wang; Huixia Zhou; Hang Xu; Yang Tian; Qilong Dai; Hanjing E Wu; Catherine Chang; Li Wang; Thomas R Kosten; Xiang Yang Zhang
Journal:  Neuropsychopharmacology       Date:  2020-04-29       Impact factor: 7.853

2.  Demographics, clinical characteristics and cognitive symptoms of heavy smokers and non-heavy smokers in Chinese male patients with chronic schizophrenia.

Authors:  Shuochi Wei; Dongmei Wang; Huixia Zhou; Luyao Xia; Yang Tian; Qilong Dai; Rongrong Zhu; Wenjia Wang; Dachun Chen; Meihong Xiu; Li Wang; Xiangyang Zhang
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2022-04-26       Impact factor: 5.760

3.  Physical Health Literacy and Health-related Behaviors in Patients with Psychosis.

Authors:  Sung-Wan Kim; Woo-Young Park; Min Jhon; Mina Kim; Ju-Yeon Lee; Seon-Young Kim; Jae-Min Kim; Il-Seon Shin; Jin-Sang Yoon
Journal:  Clin Psychopharmacol Neurosci       Date:  2019-05-31       Impact factor: 2.582

4.  Use of tobacco in schizophrenia: A double-edged sword.

Authors:  Yu Fang; Weidi Wang; Cuizhen Zhu; Guan Ning Lin; Ying Cheng; Junhui Zou; Donghong Cui
Journal:  Brain Behav       Date:  2019-10-11       Impact factor: 2.708

5.  Schizophrenia hospitalization in the US 2005-2014: Examination of trends in demographics, length of stay, and cost.

Authors:  Ethan Chen; Shahrzad Bazargan-Hejazi; Chizobam Ani; David Hindman; Deyu Pan; Gul Ebrahim; Anaheed Shirazi; Jim E Banta
Journal:  Medicine (Baltimore)       Date:  2021-04-16       Impact factor: 1.817

6.  Hospital indicators and inpatient behavior in a psychiatric hospital that implemented the smoking ban.

Authors:  Renata Marques de Oliveira; Jair Lício Ferreira Santos; Antônia Regina Ferreira Furegato
Journal:  Rev Lat Am Enfermagem       Date:  2022

7.  The Impact of the COVID-19 Pandemic on the Lifestyles and Levels of Anxiety and Depression of Patients with Schizophrenia: A Retrospective Observational Study.

Authors:  Gemma Biviá-Roig; Pau Soldevila-Matías; Gonzalo Haro; Victor González-Ayuso; Francisco Arnau; Loreto Peyró-Gregori; Laura García-Garcés; Maria I Sánchez-López; Juan Francisco Lisón
Journal:  Healthcare (Basel)       Date:  2022-01-09

8.  Smoking Affects the Patterns of Metabolic Disorders and Metabolic Syndrome in Patients With First-Episode Drug-Naive Schizophrenia: A Large Sample Study Based on the Chinese Han Population.

Authors:  Zezhi Li; Shuning Wang; Yuping Chen; Xi Wu; Yinjun Gu; Xiaoe Lang; Fengchun Wu; Xiang Yang Zhang
Journal:  Int J Neuropsychopharmacol       Date:  2021-10-23       Impact factor: 5.176

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.